Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 1/20 | 0.39 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 15/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | PPM1B | O75688 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2989012 | 0.90 | SMN1; SMN2 (0.43) | GRM5 | |
| SCHEMBL1712921 | 0.87 | CHRM1 (0.43) | CHRM1CHRM4CHRM5GRM5 | |
| SCHEMBL2995198 | 0.83 | SLC6A3 (0.34) | KCNK3KCNK9CHRM1CHRM4CHRM5 | |
| SCHEMBL12293536 | 0.82 | CHRM1 (0.42) | KCNK3KCNK9CHRM1CHRM4CHRM5 | |
| SCHEMBL14145633 | 0.79 | CHRM1 (0.56) | KCNK3KCNK9CHRM1CHRM4CHRM5 | |
| SCHEMBL12199020 | 0.79 | CHRM1 (0.43) | KCNK3KCNK9CHRM1CHRM4CHRM5 | |
| SCHEMBL1712982 | 0.79 | MEN1 (0.35) | CHRM1GRM5 | |
| SCHEMBL2999610 | 0.78 | RAB9A (0.44) | CHRM1 | |
| SCHEMBL20942090 | 0.78 | KDM4E (0.37) | KCNK3KCNK9CHRM1CHRM4CHRM5 | |
| SCHEMBL3000144 | 0.78 | CHRM1 (0.39) | CHRM1CHRM4CHRM5GRM5CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263605-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-09-11 | — | — | US | claimed |
| US-20090227614-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | claimed |
| EP-1987034-A1 | SPIRO CONDENSED PIPERIDNES AS MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmceuticals Incorporated (US) | 2008-11-05 | — | — | EP | claimed |
| WO-2007100670-A1 | SPIRO CONDENSED PIPERIDNES AS MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-07 | — | — | WO | claimed |
| US-8263605-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-09-11 | — | — | US | disclosed |
| EP-1987034-B1 | SPIRO CONDENSED PIPERIDINES AS MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMA (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20090227614-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227614-A1 | Modulators of Muscarinic Receptors | CHRM5, CHRM3, CHRM2 | KCNK3 762/4885KCNK9 691/4885CHRM1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.